SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES

被引：0
|
作者：
Sartor, O. [1 ,2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Vogelzang, N. [5 ]
Cross, A. [6 ]
O'Bryan-Tear, G. [7 ]
Staudacher, K. [7 ]
Garcia-Vargas, J. E. [8 ]
Zou, J. [9 ]
Parker, C. [10 ]
机构：
[1] Tulane Canc Ctr, Sect Hematol & Med Oncol, Dept Med, New Orleans, LA USA
[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA
[3] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] PharmaNet, Biostat, Hemel, Hempstead, England
[7] Algeta ASA, Oslo, Norway
[8] Bayer HealthCare Pharmaceut, Oncol Global Clin Programs, Montville, NJ USA
[9] Bayer HealthCare Pharmaceut, Global Med Affairs, Montville, NJ USA
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：308 / 309
页数：2
相关论文
共 50 条
  • [31] Updated survivl, Qulity of life (QOL), and safety Dta of Radium-223 Chloride (Ra-223) in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA)
    Steuber, T.
    Parker, C.
    Coleman, R. E.
    Nilsson, S.
    Volgelzang, N.
    Lloyd, A. J.
    Staudacher, K.
    van Gool, R.
    Sartor, A. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [32] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
    Vogelzang, Nicholas J.
    Helle, Svein Inge
    Johannessen, Dag Clement
    O'Sullivan, Joe M.
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
  • [34] 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Coleman, Robert E.
    Skjorestad, Irene
    Fang, Fang
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study
    Nilsson, Sten
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] Long-term safety and real world clinical experience of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the phase 3 ALSYMPCA study
    Franzen, L.
    Sartor, O.
    Parker, C.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S271 - S271
  • [38] 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Amadori, D.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Vogelzang, N. J.
    Sartor, A.
    Coleman, R. E.
    Govi, S.
    Fang, F.
    Skjorestad, I.
    Nilsson, S.
    Parker, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
  • [39] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [40] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345